Mutations of ras and p53 genes in human non-small cell lung cancer cell lines and their clinical significance

T. Mitsudomi, T. Oyama, A. F. Gazdar, J. D. Minna, K. Okabayashi, T. Shirakusa

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

We examined 77 non-small cell lung cancer (NSCLC) cell lines for mutations of 3 ras genes and p53 gene, and ras mutations were detected by designed RFLP assay generated by mismatched primers during the PCR step and p53 gene mutations were detected using SSCP analysis. The incidence of ras mutations were 27/77 (35%) while that of p53 gene mutations were 57/77 (74%). The incidence of ras mutations in cell lines with p53 mutations were not different from that without p53 mutations, suggesting that they occurred independently. Neither ras nor p53 mutations correlated with histologic subtype, disease extent, in vitro culture time nor prior therapy status. The patients whose cell lines had any ras mutations survived for shorter period of time not only among the patients who were treated with curative intent but among those treated with palliative treatment. The Cox proportional hazards model predicted the higher risk for patients with ras mutations but not those with p53 mutations. We conclude that ras and p53 mutations are frequent, apparently independent genetic alterations which play different roles in NSCLC and that this information should be utilized in surgical oncology in the near future.

Original languageEnglish (US)
Pages (from-to)944-947
Number of pages4
JournalNippon Geka Gakkai zasshi
Volume93
Issue number9
StatePublished - Sep 1992

Fingerprint

ras Genes
p53 Genes
Non-Small Cell Lung Carcinoma
Cell Line
Mutation
Single-Stranded Conformational Polymorphism
Incidence
Palliative Care
Proportional Hazards Models
Restriction Fragment Length Polymorphisms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Mitsudomi, T., Oyama, T., Gazdar, A. F., Minna, J. D., Okabayashi, K., & Shirakusa, T. (1992). Mutations of ras and p53 genes in human non-small cell lung cancer cell lines and their clinical significance. Nippon Geka Gakkai zasshi, 93(9), 944-947.

Mutations of ras and p53 genes in human non-small cell lung cancer cell lines and their clinical significance. / Mitsudomi, T.; Oyama, T.; Gazdar, A. F.; Minna, J. D.; Okabayashi, K.; Shirakusa, T.

In: Nippon Geka Gakkai zasshi, Vol. 93, No. 9, 09.1992, p. 944-947.

Research output: Contribution to journalArticle

Mitsudomi, T, Oyama, T, Gazdar, AF, Minna, JD, Okabayashi, K & Shirakusa, T 1992, 'Mutations of ras and p53 genes in human non-small cell lung cancer cell lines and their clinical significance', Nippon Geka Gakkai zasshi, vol. 93, no. 9, pp. 944-947.
Mitsudomi, T. ; Oyama, T. ; Gazdar, A. F. ; Minna, J. D. ; Okabayashi, K. ; Shirakusa, T. / Mutations of ras and p53 genes in human non-small cell lung cancer cell lines and their clinical significance. In: Nippon Geka Gakkai zasshi. 1992 ; Vol. 93, No. 9. pp. 944-947.
@article{781f4ca999394a6895a8d040e2a6f5b5,
title = "Mutations of ras and p53 genes in human non-small cell lung cancer cell lines and their clinical significance",
abstract = "We examined 77 non-small cell lung cancer (NSCLC) cell lines for mutations of 3 ras genes and p53 gene, and ras mutations were detected by designed RFLP assay generated by mismatched primers during the PCR step and p53 gene mutations were detected using SSCP analysis. The incidence of ras mutations were 27/77 (35{\%}) while that of p53 gene mutations were 57/77 (74{\%}). The incidence of ras mutations in cell lines with p53 mutations were not different from that without p53 mutations, suggesting that they occurred independently. Neither ras nor p53 mutations correlated with histologic subtype, disease extent, in vitro culture time nor prior therapy status. The patients whose cell lines had any ras mutations survived for shorter period of time not only among the patients who were treated with curative intent but among those treated with palliative treatment. The Cox proportional hazards model predicted the higher risk for patients with ras mutations but not those with p53 mutations. We conclude that ras and p53 mutations are frequent, apparently independent genetic alterations which play different roles in NSCLC and that this information should be utilized in surgical oncology in the near future.",
author = "T. Mitsudomi and T. Oyama and Gazdar, {A. F.} and Minna, {J. D.} and K. Okabayashi and T. Shirakusa",
year = "1992",
month = "9",
language = "English (US)",
volume = "93",
pages = "944--947",
journal = "Nihon Geka Gakkai zasshi",
issn = "0301-4894",
publisher = "Nihon Geka Gakkai",
number = "9",

}

TY - JOUR

T1 - Mutations of ras and p53 genes in human non-small cell lung cancer cell lines and their clinical significance

AU - Mitsudomi, T.

AU - Oyama, T.

AU - Gazdar, A. F.

AU - Minna, J. D.

AU - Okabayashi, K.

AU - Shirakusa, T.

PY - 1992/9

Y1 - 1992/9

N2 - We examined 77 non-small cell lung cancer (NSCLC) cell lines for mutations of 3 ras genes and p53 gene, and ras mutations were detected by designed RFLP assay generated by mismatched primers during the PCR step and p53 gene mutations were detected using SSCP analysis. The incidence of ras mutations were 27/77 (35%) while that of p53 gene mutations were 57/77 (74%). The incidence of ras mutations in cell lines with p53 mutations were not different from that without p53 mutations, suggesting that they occurred independently. Neither ras nor p53 mutations correlated with histologic subtype, disease extent, in vitro culture time nor prior therapy status. The patients whose cell lines had any ras mutations survived for shorter period of time not only among the patients who were treated with curative intent but among those treated with palliative treatment. The Cox proportional hazards model predicted the higher risk for patients with ras mutations but not those with p53 mutations. We conclude that ras and p53 mutations are frequent, apparently independent genetic alterations which play different roles in NSCLC and that this information should be utilized in surgical oncology in the near future.

AB - We examined 77 non-small cell lung cancer (NSCLC) cell lines for mutations of 3 ras genes and p53 gene, and ras mutations were detected by designed RFLP assay generated by mismatched primers during the PCR step and p53 gene mutations were detected using SSCP analysis. The incidence of ras mutations were 27/77 (35%) while that of p53 gene mutations were 57/77 (74%). The incidence of ras mutations in cell lines with p53 mutations were not different from that without p53 mutations, suggesting that they occurred independently. Neither ras nor p53 mutations correlated with histologic subtype, disease extent, in vitro culture time nor prior therapy status. The patients whose cell lines had any ras mutations survived for shorter period of time not only among the patients who were treated with curative intent but among those treated with palliative treatment. The Cox proportional hazards model predicted the higher risk for patients with ras mutations but not those with p53 mutations. We conclude that ras and p53 mutations are frequent, apparently independent genetic alterations which play different roles in NSCLC and that this information should be utilized in surgical oncology in the near future.

UR - http://www.scopus.com/inward/record.url?scp=0026919761&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026919761&partnerID=8YFLogxK

M3 - Article

C2 - 1361656

AN - SCOPUS:0026919761

VL - 93

SP - 944

EP - 947

JO - Nihon Geka Gakkai zasshi

JF - Nihon Geka Gakkai zasshi

SN - 0301-4894

IS - 9

ER -